Many open clinical trials are available.
If you have been diagnosed with Prostate or Bladder cancer, you may be eligible to participate in a trial. Please consult with your provider and view available trials below:
BOND-003 Cohort P
A Phase 3 Study of Cretostimogene Grenadenorepvec in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
CORE-008
A Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer
MOONRISE-1
A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations
PIVOT-006
A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT)
ProvONE P23-1
An Open-Label, Multicenter Study of Subjects With Metastatic Castrate-Resistant Prostate Cancer Treated With Provenge and Boosted With a Single Infusion of Sipuleucel-T to Measure Immune Response
Lantheus PYLARIFY Registry
A Prospective Observational Multicenter Real-World Registry Assessing the Impact of the use of PYLARIFY® (piflufolastat F 18) PET in Patients with Newly Diagnosed and Recurrent Prostate Cancer
MEVPRO-1
A Study to Learn About the Investigational Medicine Called PF-06821497 (mevrometostat) in Men with mCRPC Who Were Previously Treated with Abiraterone Acetate for Prostate Cancer (MEVPRO-1)
ORIC 944-01
An Open-Label, Phase 1/1b Study of ORIC-944 as a Single Agent or in Combination with an Androgen Receptor Pathway Inhibitor in Patients with Metastatic Prostate Cancer